Share on LinkedInShare on LinkedIn

ARTICLE · 18 MAY 2017

Supply Agreement Can Trigger On-Sale Bar

In Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., the Federal Circuit held that after the AIA, if the existence of a sale is public, the details of the invention need not be publicly...

United StatesIntellectual Property

In Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., the Federal Circuit held that after the AIA, if the existence of a sale is public, the details of the invention need not be publicly disclosed for the sale to be invalidating under 35 U.S.C. § 102, which states in relevant part: "A person shall be entitled to a patent unless the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention."

Helsinn brought suit against Teva alleging that the filing of Teva's Abbreviated New Drug Application constituted an infringement of various claims of Helsinn patents. Teva defended, inter alia, on the ground that the asserted claims were invalid under the on-sale bar provision of 35 U.S.C. § 102. The district court found that the patents-in-suit were not invalid.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from